Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
{{output}}
Background: Limited-stage small-cell lung cancer (LS-SCLC) has suboptimal long-term survival despite standard chemoradiotherapy. Durvalumab, an anti-PD-L1 antibody, demonstrated survival benefits in the ADRIATIC Phase III trial, ... ...
